Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Nat Cancer ; 2(1): 18-33, 2021 01.
Artigo em Inglês | MEDLINE | ID: mdl-35121890

RESUMO

Innate pattern recognition receptor agonists, including Toll-like receptors (TLRs), alter the tumor microenvironment and prime adaptive antitumor immunity. However, TLR agonists present toxicities associated with widespread immune activation after systemic administration. To design a TLR-based therapeutic suitable for systemic delivery and capable of safely eliciting tumor-targeted responses, we developed immune-stimulating antibody conjugates (ISACs) comprising a TLR7/8 dual agonist conjugated to tumor-targeting antibodies. Systemically administered human epidermal growth factor receptor 2 (HER2)-targeted ISACs were well tolerated and triggered a localized immune response in the tumor microenvironment that resulted in tumor clearance and immunological memory. Mechanistically, ISACs required tumor antigen recognition, Fcγ-receptor-dependent phagocytosis and TLR-mediated activation to drive tumor killing by myeloid cells and subsequent T-cell-mediated antitumor immunity. ISAC-mediated immunological memory was not limited to the HER2 ISAC target antigen since ISAC-treated mice were protected from rechallenge with the HER2- parental tumor. These results provide a strong rationale for the clinical development of ISACs.


Assuntos
Imunoterapia , Neoplasias , Imunidade Adaptativa , Animais , Antígenos de Neoplasias , Imunoterapia/métodos , Camundongos , Neoplasias/tratamento farmacológico , Microambiente Tumoral
2.
Curr Opin Mol Ther ; 4(5): 476-81, 2002 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-12435049

RESUMO

Coronary artery disease (CAD) and peripheral vascular disease (PVD) are significant medical problems worldwide, and arguably the biggest medical problems in the developed world. Although substantial progress has been made in prevention as well as in the treatment of these diseases, particularly of CAD, there are a large number of patients, who despite maximal medical treatment, have substantial symptomatology, and who are not candidates for mechanical revascularization. Therapeutic angiogenesis represents a novel, conceptually appealing, treatment option for these patients. Consequently, there are several different products in clinical trials, looking at various angiogenic growth factors. A number of small, mostly open-labeled phase I or phase I/II studies have been conducted with adeno- and plasmid-based vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) gene constructs in CAD and PVD. Although these studies have provided intriguing indications that new vessel formation is possible, and that these new vessels could be functional, these studies have been too small to allow conclusions to be drawn about potential efficacy. A number of proof-of-concept studies are presently underway or planned with four different constructs Ad(GV)VEGF121.10 (BioByPass; GenVec Inc), ph-VEGF (St Elizabeth's Medical Center of Boston Inc), Ad5-FGF4 (Collateral Therapeutics Inc/Schering Inc) and NV1FGF (Aventis Pharma AG/Aventis Gencell), and should, upon completion, provide a better indication as to the potential therapeutic role of these treatment modalities in the armamentarium against atherosclerotic disease. This exciting new field is reviewed, with special emphasis on clinical trials.


Assuntos
Doenças Cardiovasculares/terapia , Terapia Genética , Neovascularização Patológica/genética , Fatores de Crescimento de Fibroblastos/genética , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...